RZLT earnings analysis
What we found in RZLT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Rezolute, Inc. (RZLT) reported no generated revenue for Q3 2026, maintaining a net loss of $16.2 million, slightly improved from $18.9 million loss in Q3 2025. The total cash and equivalents decreased to $120.2 million from $167.9 million year-over-year, reflecting ongoing challenges in the clinical trial landscape, particularly related to their sunRIZE study. Management remains focused on the next steps in their clinical programs and anticipates future engagements with the FDA.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Narrowed Net Loss Year-over-Year
- Net loss for Q3 2026 was $16.2 million, down from $18.9 million in Q3 2025.
- Cash Position
- Cash and cash equivalents decreased to $120.2 million as of March 31, 2026, down from $167.9 million a year prior.
- Decrease in R&D Expenses
- R&D expenses decreased by $3.9 million to $11.4 million in Q3 2026, down from $15.3 million in Q3 2025.
- Increase in General and Administrative Expenses
- G&A expenses increased by 25.6% to $5.95 million in Q3 2026 compared to $4.74 million in Q3 2025.
- Operating Cash Flow
- Cash used in operating activities amounted to $51.5 million for the nine months ended March 31, 2026, compared to $47.1 million for the same period last year.
- Interest Income Rise
- Interest and other income increased to $1.2 million in Q3 2026 from $1.1 million in Q3 2025, due to higher average investments.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Accumulated Deficit
- The cumulative net losses have reached $461.0 million since inception.
- Regulatory Hurdles for sunRIZE Study
- The FDA may challenge the results of the sunRIZE study due to its failure to meet primary endpoints.
- Financial Viability Concerns
- The company may require additional financing to support operations beyond the next 12 months.
What they said about what is next.
No numeric guidance was provided; focus remains on clinical studies.
The filing reads about the same as the one before it.
What came before.
- 10-Q · February 12, 2026
- Rezolute reported no revenue and a wider quarterly net loss of $22.774 million (three months ended December 31, 2025) versus $15.730 million in the prior-year quarter, with GAAP loss per share of $(0.22). Cash and cash…
- 10-Q · May 13, 2025
- Rezolute reported a net loss of $18.9M (three months ended March 31, 2025) and GAAP diluted loss per share of $(0.27). Operating expenses rose as R&D increased to $15.283M (Q3) and total operating loss widened to…
- 10-K · September 19, 2024
- Rezolute advanced its lead program ersodetug into pivotal Phase 3 programs (sunRIZE for congenital HI and a Phase 3 registrational study for tumor HI) with topline readouts expected in calendar 2025, and reported…
- 10-Q · May 11, 2023
- Rezolute reported a net loss of $15,672,000 (EPS $(0.30)) for the three months ended March 31, 2023, driven by higher R&D and G&A spending. Cash and short- and long-term marketable debt securities totaled $129,272,000…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing RZLT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever